Theravance Biopharma, Inc. (TBPH) News
Track canonical SquawkNews coverage tagged to TBPH, Theravance Biopharma, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 2 indexed stories across 1 publication days and is ordered by the same first-publication timeline used by LiveCast.
M
Theravance Biopharma Discloses Termination Fee Of $32.5M After Acquisition Offer By Zymeworks
The Merger Agreement contains certain customary termination rights for the Company and Parent. Subject to the terms and conditions of the Merger Agreement, the Company or Parent may terminate the Merger Agreement if the
MNA | Jun 29, 2026, 10:43 AM UTC
H
Zymeworks To Acquire Theravance Biopharma At $17 Per Share For Total Cash Consideration Of $929M
Acquisition adds YUPELRI® (revefenacin), the first and only approved nebulized long-acting muscarinic antagonist (LAMA) for the maintenance treatment of COPD to Zymeworks' portfolio Acquisition of Theravance Biopharma at
EARNINGS | Jun 29, 2026, 10:04 AM UTC